반응식
[CH3:1][C:2]1[C:6]([CH2:7][N:8]2[CH:12]=[C:11]([N:13]3[C:17](=[O:18])[C:16]([CH3:20])([CH3:19])[NH:15][C:14]3=[O:21])[CH:10]=[N:9]2)=[C:5]([CH3:22])[O:4][N:3]=1.Cl[CH2:24][C:25]1[CH:30]=[C:29]([O:31][CH3:32])[CH:28]=[C:27]([O:33][CH3:34])[CH:26]=1>>[CH3:34][O:33][C:27]1[CH:26]=[C:25]([CH:30]=[C:29]([O:31][CH3:32])[CH:28]=1)[CH2:24][N:15]1[C:16]([CH3:19])([CH3:20])[C:17](=[O:18])[N:13]([C:11]2[CH:10]=[N:9][N:8]([CH2:7][C:6]3[C:2]([CH3:1])=[N:3][O:4][C:5]=3[CH3:22])[CH:12]=2)[C:14]1=[O:21]참가 물질
3
실험 절차
Prepared as in Example 12-16 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione (Example 12-16a) and 1-(chloromethyl)-3,5-dimethoxybenzene. MS 454 (MH+). The title compound was shown to inhibit hT2R08 bitter receptor and had an IC50 of 0.3 μM.
출처 및 근거
- ORD 기록
- ord-d5ef61573a5544519b6f1f4ae0948521
- 출처 데이터셋
- uspto-grants-2013_05
- 특허 번호
- US08445692B2
연결된 노트
불러오는 중…